

News Article downloaded from - <http://www.bioportfolio.com> on Friday, November 27, 2009
Read [CeNeS Announces New Scientific Advisory Board](#) on BioPortfolio.com
(http://www.bioportfolio.com/news/CeNeS_Announces_New_Scientific_Advisory_Board.html)

CeNeS Announces New Scientific Advisory Board

Friday 1st of April 2005 8:00

CeNeS Announces New Scientific Advisory Board

Cambridge, UK, 25 April 2005 - CeNeS Pharmaceuticals plc (AIM: CEN) ("CeNeS" or "the Company") today announced the appointment of a new Scientific Advisory Board (SAB). The SAB will meet regularly to provide CeNeS with scientific and clinical guidance for its research and development activities.

The company has appointed Dr Ann Hayes, an independent industry consultant in the CNS area, Professor David Brooks of the Division of Neuroscience, Imperial College London, Dr Mick Serpell of the Department of Anaesthesia, University of Glasgow, and Dr David Brown who has had a variety of research and executive roles in the biopharmaceutical industry. Together they bring a range of expertise in CNS disorders, drug discovery and development, and industry expertise to CeNeS.

"We are delighted that the highest calibre scientists have decided to join our SAB," said Neil Clark, CEO of CeNeS. "With their recognised knowledge of CNS drug discovery and development and expertise in pain, anaesthesia and Parkinson's disease, they will provide excellent support to our drug development programmes".

Ann Hayes, who will chair the SAB, commented "CeNeS has a logical, lower-risk approach to drug discovery and an exciting portfolio ranging from candidates at the lead optimisation stage through to M6G which is in Phase III clinical trials for post-operative pain. I am very pleased to be part of the impressive team of advisors that has been assembled and look forward to contributing to the progression of CeNeS' programmes".

ENDS

Notes to editors:

The CeNeS SAB members are as follows:

Ann Hayes Ph.D

Ann worked for 22 years for GlaxoWellcome specialising in the areas of CNS and pain. She was a Director in Drug Discovery, with particular expertise in determining long-term discovery strategy, in portfolio management and in discovery project management. After leaving GSK in 2001, Ann set up a business as an independent pharmaceutical consultant. In this capacity she has co-founded two companies, Ionix Pharmaceuticals and TheraSci, which has since been bought by CeNeS. Ann is a non-executive director of the biotechnology companies Ionix and Curidium, a member of the

Scientific Advisory Board for Biowisdom and has also been non-executive director at TheraSci and Sirus (which was recently sold to Arakis).

David J Brooks MD DSc FRCP FMed Sci

David Brooks is Hartnett Professor of Neurology and Head of the Department of Sensorimotor Systems in the Division of Neuroscience, Faculty of Medicine, Imperial College, London. He is also Head of the Neurology Group at the Medical Research Council Clinical Sciences Centre, Hammersmith Hospital, London. Additionally, he is Chief Medical Officer of Imanet, GE Healthcare PLC. David is a member of the International Research Advisory Board of several organisations including the Michael J. Fox Foundation for Parkinson's Disease Research and the Medical Research Council Neuroscience and Mental Health board. David is on the Editorial Boards of several journals. In 2001 he was elected a Fellow of the Academy of Medical Science, UK. His research involves the use of positron emission tomography and magnetic resonance imaging to study cerebral control of movement and performance in therapeutic trials for Parkinson's, Huntington's, and Alzheimer's diseases. To date, he has published over 250 reports in peer reviewed journals, including Nature.

Mick Serpell, MB ChB, FChP, ECFMG, FRCA

Mick Serpell graduated from Medical School at the University of Dundee in 1983. He completed his training in Anaesthesia and Pain Management in Dundee, Scotland, Orebro in Sweden and Dartmouth Hitchcock Medical Centre in New Hampshire, USA. He took up his Consultant post in Glasgow in 1993 and became Senior Lecturer at the University of Glasgow Department of Anaesthesia in 1999. His research interests include pharmacological and regional analgesia management of acute and chronic pain. He is particularly interested in the diagnosis and early treatment of neuropathic pain. He leads the Clinical Trials Unit at the Pain Clinic in Gartnavel. He has undertaken 24 commercial studies over the past six years, and is on the Advisory Board of four commercial companies. He is Chairman of the Research and Priority Programme for Pain & Acute Medicine for the Glasgow Acute Hospital Trusts. Mick is Lead Clinician in Chronic Pain for North Glasgow and Chairs the Neuropathic Pain Special Interest Group (British Pain Society).

David Brown PhD, FRSC

David Brown has over 30 years experience in the pharmaceutical / biotechnology industry both in research and in senior executive roles. From 1974-2002 he served with four of the top 10 Pharma companies: Zeneca, Pfizer, Glaxo, and most recently with F. Hoffman La-Roche as Global Head of Drug Discovery. In this role he had responsibility for the output of clinical candidate drugs from approximately 2000 scientists across Roche's five research sites. From 2002-2004 David was President and CEO of Cellzome AG, a biotechnology company headquartered in Heidelberg, Germany. David has extensive experience of pharmaceutical R&D. Whilst at Pfizer he was named co-inventor on the patent for Viagra, a treatment for male impotence, and led the team that developed Viagra through to proof of clinical efficacy in man. He also played a key role in the discovery of Relpax, a treatment for migraine. David is now an independent pharmaceutical consultant

About CeNeS Pharmaceuticals

CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: www.cenes.com.

For further information please contact:

CeNeS Pharmaceuticals plc:

Alan Goodman/Neil Clark

Tel: +44 (0)1223 266466

Fax: +44 (0)1223 266467

Northbank Communications

Media Enquiries:

Rowan Minnion

Tel: +44 (0)20 7886 8154

Financial Enquiries:

Emma Palmer

Tel: +44 (0)20 7886 8159

Via PR Newswire - PRNewswire.co.uk

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

